Table 2.

MR results and sensitivity analyses between steroid hormones and glaucoma.

	P (MR results)					P (Cochrane's Q)		P (Pleiotropy)
	IVW	MR-Egger	WM	MLE	MR-RAPS	IVW	MR-Egger	MR-Egger regression	MR-PRESSO
Discovery stage
Aldo	0.25	0.35	0.88	0.65	0.66	0.97	0.99	0.14	0.918
A4	0.35	0.98	0.99	0.55	0.57	0.68	0.64	0.59	0.767
P4	0.93	0.51	0.82	0.85	0.85	0.91	0.91	0.41	0.698
17-OHP	0.77	0.25	0.82	0.51	0.52	0.82	0.91	0.19	0.769
T/E2	0.03	0.19	0.04	0.03	0.03	0.62	0.57	0.58	0.679
Replicated stage
Aldo	0.93	0.20	0.67	0.75	0.76	0.81	0.95	0.20	0.735
A4	0.35	0.75	0.80	0.32	0.35	0.87	0.81	0.66	0.935
P4	0.17	0.16	0.06	0.69	0.67	0.17	0.47	0.11	0.057
17-OHP	0.43	0.45	0.07	0.55	0.55	0.09	0.08	0.49	0.133
T/E2	0.04	0.44	0.11	0.04	0.05	0.65	0.77	0.29	0.675

MR, Mendelian randomization; IVW, Inverse variance weighted; WM, Weighted median; MLE, maximum likelihood estimator; MR-RAPS, MR robust adjusted profile score; Aldo, aldosterone; A4, androstenedione; P4, progesterone; 17-OHP, hydroxyprogesterone; T/E, Testosterone_Estradiol_Ratio.